Current Concept in Management of High Risk Prostate Cancer

Assisstant Professor Choosak Pripatnanont, MD

Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand

Julin Opanurak, MD

Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

Associate Professor Kittinut Kijvikai, MD

Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

Associate Professor Thawatchai Taweemonkongsap, MD

Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand


The definition of high-risk prostate cancer is still heterogeneous, but it is most commonly defined as men having one or more of these features: initial PSA >20 ng/ml, biopsy Gleason score >7, and clinical stage T≥2c. High-risk prostate cancer is clearly the most concerning form of localized disease with 35.5% cumulative mortality at 15 yr. For many years an aggressive local therapy, either by external beam radiotherapy (EBRT) or surgery, was offered as principal or sole therapy for high- risk PC patients. The field is now in evolution, with more promising results from multimodal therapies next to EBRT or RP. This session will review in detail of treatment based on current guideline and practice including case discussion. 

Event Hours(1)

  • Lotus 1-2

    01:00 pm – 02:15 pm

    1. Asst. Prof. Choosak Pripatnanond (CRA)
    2. Dr. Julin Opanuraks (CU)
    3. Assoc. Prof. Kittinut Kijvikai (Rama)
    4. Assoc. Prof. Thawatchai Taweemonkongsap (SI)

    Asst. Prof. Choosak Pripatnanond (CRA)